Orilissa vs Myfembree
A side-by-side look at two women's health medications advertised on TV. Informational only — not medical advice.
| US Orilissa | US Myfembree | |
|---|---|---|
| Generic name | elagolix | relugolix/estradiol/norethindrone |
| Drug class | GnRH Antagonist | GnRH Antagonist Combination |
| Treats | Endometriosis pain | Uterine fibroids and endometriosis |
| Category | Women's Health | Women's Health |
| Manufacturer | AbbVie | Myovant Sciences |
| Year approved | 2018 | 2021 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $60M | — |
| Common side effects | Hot flashes, Headache, Nausea, Bone density loss | Bone density loss, Blood clot risk, Hot flashes, Abnormal bleeding |
Myfembree
Frequently asked questions
Is Orilissa or Myfembree better?
Neither is universally "better." Orilissa (elagolix) and Myfembree (relugolix/estradiol/norethindrone) are both used for women's health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Orilissa and Myfembree?
Orilissa is a GnRH Antagonist made by AbbVie, while Myfembree is a GnRH Antagonist Combination made by Myovant Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Orilissa has the larger estimated TV advertising budget of the two.